Group 1 - The core viewpoint of the news is that the avian influenza concept sector has seen a significant increase, ranking fourth among concept sectors with a rise of 2.33% as of the market close on July 16 [1][2]. - Within the avian influenza sector, 24 stocks experienced gains, with notable performers including Biological Shares and Lianhuan Pharmaceutical, which hit the daily limit, and others like Ruipu Biological and Zhongmu Shares, which rose by 5.65%, 3.70%, and 3.56% respectively [1][2]. - The avian influenza concept sector attracted a net inflow of 301 million yuan from main funds today, with 12 stocks receiving net inflows, and 6 stocks seeing inflows exceeding 10 million yuan [2][3]. Group 2 - The leading stocks in terms of net fund inflow within the avian influenza concept include Biological Shares with a net inflow of 159 million yuan, followed by Lianhuan Pharmaceutical and Zhongsheng Pharmaceutical with inflows of 95.22 million yuan and 70.42 million yuan respectively [2][3]. - The net inflow ratios for the top stocks are as follows: Biological Shares at 19.39%, Lianhuan Pharmaceutical at 11.66%, and Zhongsheng Pharmaceutical at 5.64% [3][4]. - The trading volume and turnover rates for the leading stocks in the avian influenza sector indicate strong investor interest, with Biological Shares showing a turnover rate of 8.74% and Lianhuan Pharmaceutical at 18.86% [3][4].

Core Viewpoint - The company, Zhongsheng Pharmaceutical, is experiencing significant growth in its half-year performance, with net profit expected to increase by 94.49% to 140.25% year-on-year, indicating a positive outlook for its annual performance and reflecting the gradual absorption of the negative impacts from centralized procurement [1][6]. Financial Performance - The expected net profit for the first half of 2025 is approximately 170 million to 210 million yuan, with a non-GAAP net profit forecasted at 180 million to 220 million yuan, representing a year-on-year growth of 3.64% to 26.67% [1]. Innovation in Drug Development - The company has made significant breakthroughs in its three core innovative drug platforms targeting influenza, COVID-19, and metabolic diseases, positioning itself as a leader in the competitive pharmaceutical landscape [2][5]. - The launch of "Angladi" as the world's first targeted influenza treatment has been a pivotal moment, demonstrating a new paradigm in flu therapy and showing promising clinical results [3]. - "Lai Ru Te Wei," a novel single-drug treatment for COVID-19, has been recognized for its efficacy and safety, filling a critical gap in the domestic market for oral COVID-19 medications [4]. Market Position and Strategy - The company is accelerating its transition to innovative drug development, supported by a strategic shift in funding towards new drug research, particularly in influenza and diabetes [6]. - The Chinese pharmaceutical market is undergoing a transformation, with a clear trend towards globalization of innovative drugs, and Zhongsheng Pharmaceutical is positioned to benefit from this trend [7][8]. - The company’s traditional Chinese medicine segment remains a stable foundation for its overall performance, with significant revenue contributions expected despite short-term impacts from centralized procurement [7]. Future Outlook - The combination of innovative drug development and a solid foundation in traditional Chinese medicine is expected to drive the company's growth, with a focus on addressing public health challenges and enhancing its global presence [8].

证券代码：002317 公告编号：2025-070 广东众生药业股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 （一）业绩预告期间：2025 年 1 月 1 日至 2025 年 6 月 30 日。 （二）预计的业绩： ?亏损 ?扭亏为盈 √同向上升 ?同向下降 项目 本报告期 上年同期 归属于上市公司股东 盈利：17,000 万元–21,000 万元 盈利：8,740.98 万元 的净利润 比上年同期上升：94.49%–140.25% 扣除非经常性损益后 盈利：18,000 万元–22,000 万元 盈利：17,368.16 万元 的净利润 比上年同期上升：3.64%–26.67% 基本每股收益 盈利：0.20 元/股–0.25 元/股 盈利：0.10 元/股 二、与会计师事务所沟通情况 本次业绩预告未经注册会计师预审计。 三、业绩变动原因说明 公司预计 2025 年半年度归属于上市公司股东的净利润较去年同期增长 经常性损益为-8,627.19 万元，主要为公司持有的纳入交易性金融资产的股票发 生公允价值变动以及公司计提未决 ...

智通财经7月14日电，众生药业(002317.SZ)发布2025年半年度业绩预告，预计归属于上市公司股东的净 利润为17,000万元–21,000万元，比上年同期增长94.49%～140.25%。净利润变动主要原因是去年同期非 经常性损益项目的影响。去年同期非经常性损益为-8,627.19万元，主要为公司持有的纳入交易性金融资 产的股票发生公允价值变动以及公司计提未决诉讼预计负债所致。本报告期非经常性损益对净利润影响 减少。 众生药业：上半年净利同比预增94.49%-140.25% ...

[Current Period Performance Forecast](index=1&type=section&id=I.%E3%80%81Current%20Period%20Performance%20Forecast) This section outlines the company's semi-annual performance forecast for 2025, detailing the projected net profit and earnings per share [Performance Forecast Period](index=1&type=section&id=(I)%20Performance%20Forecast%20Period) The company forecasts its semi-annual performance for 2025, covering financial results from January 1 to June 30, 2025 - The performance forecast period is from **January 1, 2025, to June 30, 2025**[3](index=3&type=chunk) [Projected Performance](index=1&type=section&id=(II)%20Projected%20Performance) Net profit attributable to shareholders for the first half of 2025 is projected to increase significantly by 94.49% to 140.25%, with non-recurring net profit expected to grow by 3.64% to 26.67% Key Performance Indicators Forecast for H1 2025 | Item | Current Period Forecast (CNY 10,000) | Prior Year Period (CNY 10,000) | Year-over-Year Change Range | | :-------------------------------- | :--------------------------------- | :----------------------------- | :-------------------------- | | Net Profit Attributable to Shareholders | 17,000 – 21,000 | 8,740.98 | Increase 94.49% – 140.25% | | Net Profit Excluding Non-Recurring Items | 18,000 – 22,000 | 17,368.16 | Increase 3.64% – 26.67% | | Basic Earnings Per Share (CNY/share) | 0.20 – 0.25 | 0.10 | - | [Communication with Accounting Firm](index=1&type=section&id=II.%E3%80%81Communication%20with%20Accounting%20Firm) This section clarifies that the current performance forecast has not undergone pre-audit by a certified public accountant - This performance forecast has not been pre-audited by a certified public accountant[4](index=4&type=chunk) [Explanation of Performance Changes](index=1&type=section&id=III.%E3%80%81Explanation%20of%20Performance%20Changes) The significant increase in net profit attributable to shareholders is primarily attributed to the reduced impact of non-recurring gains and losses compared to the prior year period - Net profit attributable to shareholders is projected to increase significantly by **94.49% to 140.25%**, primarily due to the impact of non-recurring gains and losses in the prior year period[5](index=5&type=chunk) - Non-recurring gains and losses in the prior year period amounted to **-86.2719 million yuan**, mainly comprising fair value changes in tradable financial assets and provisions for pending litigation[5](index=5&type=chunk) - The impact of non-recurring gains and losses on net profit decreased in the current reporting period[5](index=5&type=chunk) [Other Related Information](index=2&type=section&id=IV.%E3%80%81Other%20Related%20Information) This section provides disclaimers regarding the preliminary nature of the forecast and advises investors to exercise caution - This performance forecast represents preliminary estimates by the company's finance department and has not been audited by an accounting firm[7](index=7&type=chunk) - Specific financial data will be detailed in the company's 2025 semi-annual report[7](index=7&type=chunk) - The company advises investors to be aware of investment risks[7](index=7&type=chunk)

Investment Rating - The report maintains an optimistic outlook on the pharmaceutical industry, particularly for 2025, suggesting a potential for diverse investment opportunities as the sector recovers from low valuations and public fund allocations [10]. Core Insights - The pharmaceutical sector is currently experiencing low valuations, with public funds under-allocating to this area. The report anticipates a recovery driven by macroeconomic factors and significant product launches [10]. - The report emphasizes a shift in the innovative drug sector from quantity to quality, highlighting the importance of differentiated products and international expansion for profitability [10]. - The medical device sector is seeing a rebound in bidding volumes, particularly in imaging equipment, and is expected to benefit from domestic product upgrades and international market expansion [10]. - The report identifies a growing trend in the CXO and life sciences services sector, with expectations for increased investment and a recovery in demand [10]. - The traditional Chinese medicine sector is projected to benefit from policy changes and market dynamics, with specific companies recommended for investment based on their unique product offerings and market positions [12]. Summary by Sections Market Review - The report notes a 1.80% increase in the CITIC Pharmaceutical Index, outperforming the CSI 300 Index by 0.98 percentage points, ranking 16th among 30 sectors [7]. - The top-performing stocks include Frontline Bio-U, MediWest, and Lianhuan Pharmaceutical, while the worst performers include ST Weiming and Innovent Biologics [7]. Overall Perspective and Investment Themes - The report suggests that the pharmaceutical industry is poised for growth, with a focus on innovative drugs, medical devices, and traditional Chinese medicine. Specific companies are highlighted for their potential in these areas [10][12]. - The report also discusses the implications of policy changes and market trends for the pharmaceutical and medical device sectors, indicating a favorable environment for investment [10][12]. Company-Specific Insights - Companies like Baiyi, Xinda, and Kangfang are highlighted for their innovative drug pipelines and potential for growth in the coming years [10][12]. - The report provides detailed insights into the clinical progress of various drugs across different companies, indicating a robust pipeline that could drive future revenue [13][20][24][30][35][38].

Market Review - The CITIC Pharmaceutical Index increased by 1.80%, outperforming the CSI 300 Index by 0.98 percentage points, ranking 16th among 30 CITIC first-level industry indices [5] - The top ten stocks by increase this week include Frontier Biologics-U, Medici, Lianhuan Pharmaceutical, Kangchen Pharmaceutical, and others, with Frontier Biologics-U leading at 41.43% [4][5] - The bottom ten stocks by decrease include ST Weiming, Shenzhou Cell, and Shuotai Shen, with ST Weiming dropping by 18.51% [4][5] Overall Viewpoint and Investment Themes - The current valuation of the pharmaceutical sector is at a low point, with public funds (excluding pharmaceutical funds) having low allocation to the sector. The company remains optimistic about the growth of the pharmaceutical industry by 2025, driven by macroeconomic factors and the demand from major categories [9] - In the innovative drug sector, there is a shift from quantity logic to quality logic, focusing on differentiated domestic and international pipelines. The company suggests paying more attention to products and companies that can ultimately realize profits [9] - In the medical device sector, there is a noticeable recovery in bidding volumes for imaging equipment, and the home medical device market is expected to benefit from subsidy policies. The company highlights the potential for import substitution and growth in the orthopedic sector post-collection [9] - The innovation chain (CXO + life sciences services) is expected to see a rebound in overseas investment and a bottoming out in domestic investment, with a potential return to high growth by 2025 [9] - The pharmaceutical industry is anticipated to enter a new growth cycle, with a focus on specialty raw materials and the expiration of patents leading to new growth opportunities [9] Industry and Company Events - The company highlights the innovative layout of traditional Chinese medicine enterprises, with several products in clinical II and III phases, including those targeting chronic insomnia and primary acute gouty arthritis [29][30] - Yunnan Baiyao has several drugs in various clinical stages, including those for prostate cancer and other conditions, indicating a robust pipeline [16][19] - The company emphasizes the importance of the blood products sector, which is expected to see significant growth due to relaxed approval processes and increased production capacity [14] - The innovative drug pipeline of Yiling Pharmaceutical focuses on cardiovascular, respiratory, and endocrine diseases, with multiple drugs in clinical trials [20][21]

Group 1 - The weight loss drug concept sector experienced a decline of 1.10%, ranking among the top declines in concept sectors, with notable declines from companies like Kexing Pharmaceutical, Yipinhong, and Ganli Pharmaceutical [1][2] - Among the 17 stocks that rose, Tainkang, *ST Sansheng, and Lanxiao Technology led with increases of 4.12%, 3.21%, and 2.31% respectively [1][2] - The weight loss drug sector saw a net outflow of 683 million yuan from main funds, with 33 stocks experiencing outflows, and 8 stocks seeing outflows exceeding 30 million yuan [2][4] Group 2 - Kexing Pharmaceutical had the highest net outflow of main funds at 116 million yuan, followed by Hanyu Pharmaceutical and Ganli Pharmaceutical with outflows of 112 million yuan and 109 million yuan respectively [2][4] - The stocks with the highest net inflow of main funds included Tainkang, Zhongsheng Pharmaceutical, and Changshan Pharmaceutical, with inflows of 34.43 million yuan, 23.74 million yuan, and 20.84 million yuan respectively [2][4] - The trading volume for Kexing Pharmaceutical was 7.99%, with a price drop of 14.19%, indicating significant trading activity despite the decline [3][4]

Market Overview - The Shanghai Composite Index rose by 0.18% on July 3, with 24 out of the 28 sectors in the Shenwan classification experiencing gains. The leading sectors were electronics and electrical equipment, with increases of 1.69% and 1.38% respectively. The pharmaceutical and biological sector ranked third in terms of gains [1] - The coal and transportation sectors saw the largest declines, with decreases of 1.16% and 0.28% respectively [1] Fund Flow Analysis - The main funds in the two markets experienced a net outflow of 4.511 billion yuan throughout the day. Nine sectors saw net inflows, with the electronics sector leading at a net inflow of 7.820 billion yuan, followed by the pharmaceutical and biological sector with a net inflow of 1.382 billion yuan [1] - A total of 22 sectors experienced net outflows, with the machinery equipment sector leading at a net outflow of 2.317 billion yuan, followed by the basic chemicals sector with a net outflow of 1.908 billion yuan [1] Pharmaceutical and Biological Sector Performance - The pharmaceutical and biological sector increased by 1.35% with a net inflow of 1.382 billion yuan. Out of 474 stocks in this sector, 388 stocks rose, and 12 stocks hit the daily limit up. Conversely, 83 stocks declined [2] - Among the stocks with net inflows exceeding 100 million yuan, Huahai Pharmaceutical led with a net inflow of 269 million yuan, followed by Changchun High-tech and Zhongsheng Pharmaceutical with net inflows of 266 million yuan and 178 million yuan respectively [2] - The stocks with the largest net outflows included Dongfang Ocean, Changshan Pharmaceutical, and Mindray Medical, with net outflows of 186 million yuan, 155 million yuan, and 121 million yuan respectively [2][3] Top Gainers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Huahai Pharmaceutical: +10.01%, turnover rate 4.98%, net inflow 268.63 million yuan - Changchun High-tech: +10.00%, turnover rate 4.06%, net inflow 266.41 million yuan - Zhongsheng Pharmaceutical: +6.22%, turnover rate 13.53%, net inflow 177.88 million yuan [2] Top Losers in Pharmaceutical Sector - The top losers in the pharmaceutical sector included: - Dongfang Ocean: -1.29%, turnover rate 25.09%, net outflow -186.29 million yuan - Changshan Pharmaceutical: +0.41%, turnover rate 2.88%, net outflow -154.59 million yuan - Mindray Medical: -2.13%, turnover rate 0.63%, net outflow -120.66 million yuan [3]

Group 1 - The innovative drug concept sector rose by 2.49%, ranking 7th among concept sectors, with 196 stocks increasing in value [1] - Notable gainers included Guoshentang and Shenzhou Cell, both reaching a 20% limit up, while stocks like Jiuzhitang, Weiming Pharmaceutical, and Huahai Pharmaceutical also hit the limit up [1] - The top gainers in the sector included Shanghai Yizhong, Saiseng Pharmaceutical, and Rejing Biomedical, with increases of 10.82%, 10.45%, and 10.38% respectively [1] Group 2 - The innovative drug sector saw a net inflow of 1.887 billion yuan, with 122 stocks receiving net inflows, and 6 stocks exceeding 100 million yuan in net inflow [2] - Huahai Pharmaceutical led the net inflow with 269 million yuan, followed by Changchun Gaoxin, Zhongsheng Pharmaceutical, and Jiuzhitang with net inflows of 266 million yuan, 178 million yuan, and 172 million yuan respectively [2] - The stocks with the highest net inflow ratios included Jiuzhitang, Weiming Pharmaceutical, and Huahai Pharmaceutical, with net inflow ratios of 33.17%, 24.18%, and 17.37% respectively [3] Group 3 - The innovative drug sector's top stocks by trading volume included Huahai Pharmaceutical, Changchun Gaoxin, and Zhongsheng Pharmaceutical, with trading volumes of 26.863 million yuan, 26.640 million yuan, and 17.787 million yuan respectively [3][4] - Other notable stocks included Guoshentang, which had a trading volume of 13.697 million yuan, and Weiming Pharmaceutical with 8.946 million yuan [4] - The sector's performance was characterized by significant trading activity, with many stocks experiencing high turnover rates [4]